The pill version of Wegovy: what you need to know before asking your prescriber

Step 1: understanding what the tablet actually contains

Semaglutide is a GLP-1 receptor agonist — it mimics a gut hormone that signals fullness and slows the rate at which the stomach empties. The injection delivers it directly under the skin once a week. The tablet uses a different approach: semaglutide is co-formulated with an absorption enhancer called SNAC, which allows it to cross the stomach lining and reach the bloodstream when swallowed.

If you've already been reading about the Wegovy tablet, you'll know this is a genuinely new formulation rather than a reformatted version of the pen. The mechanism of appetite suppression is the same; the delivery method is entirely different. One practical consequence is that timing matters far more with the tablet than with an injection. You take it first thing in the morning on an empty stomach, with a small amount of plain water (up to around 120 ml). Nothing else (no coffee, no food, no other oral medicines) for at least 30 minutes afterwards. That waiting window is the price of the needle-free format.

It is also worth knowing that semaglutide tablets already exist under a different brand name, Rybelsus, but those are licensed for type 2 diabetes at different strengths (3 mg, 7 mg and 14 mg). The Wegovy weight-loss tablet schedule (1.5 mg, 4 mg, 9 mg and 25 mg) is a separate product for a separate indication. The two should not be confused.

Step 2: the titration process and what the 25 mg dose actually means

Treatment does not start at the maintenance dose. The prescriber begins at 1.5 mg to let your digestive system settle, then steps up through 4 mg and 9 mg before reaching 25 mg, spending a minimum of one month at each level. That gradual climb is deliberate, gastrointestinal side effects are the most common complaint with semaglutide in any form, and slower escalation gives most people a much easier time of it.

If you are already established on the 2.4 mg weekly injection, your prescriber may be able to move you directly to the 25 mg tablet rather than starting from the bottom, though that decision rests entirely on clinical assessment. Details of how that transition works are covered on the semaglutide formulation conversion page for anyone switching between versions.

Side effects mirror the injection's profile: nausea, vomiting, diarrhoea and constipation are most commonly reported. In the OASIS 4 trial, 74% of participants on oral semaglutide reported gastrointestinal events, versus 42% on placebo. Most were mild to moderate and settled over time. The full side-effect picture is set out in the NHS semaglutide medicines page, which covers both the injection and tablet formulations. As with any medicine in this class, severe or persistent stomach pain that radiates to the back warrants urgent medical attention, contact a doctor or call 111 rather than waiting it out.

Step 3: reading the trial results honestly

The OASIS 4 phase 3 trial followed 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks, alongside lifestyle support, and the headline from that data is an average weight loss of around 13.6% on oral semaglutide compared with around 2.4% on placebo. Among participants who remained fully adherent throughout, the average reached approximately 16–17%. That higher figure is worth knowing about, but it is the adherent-population result rather than the intention-to-treat average, both are real, and a prescriber can help you understand what they mean for your own situation.

For context on how this compares with the injection or with tirzepatide, the oral versus injection comparison page runs through the numbers side by side. The short version is that 13.6% average weight loss sits below the injection's 15% (STEP 1, 68 weeks at 2.4 mg) and some distance from tirzepatide's headline figures, but for people who cannot or simply would not use a weekly injection, it is a clinically meaningful outcome, and the MHRA's approval reflects that. The MHRA's semaglutide approval news provides the regulatory context for anyone who wants to verify the UK licensing status directly.

If you find yourself somewhere in between (curious enough to look this up but not yet sure whether the tablet or the injection is the better fit for your life) that is exactly the kind of question a prescriber is there to help with. Our clinical team reviews consultations the same day; you can check your eligibility and start a free consultation whenever you're ready.

Step 4: NHS availability and what private access currently looks like

As of summer 2026, the oral version of Wegovy has no NHS funding pathway. NICE would need to complete a separate technology appraisal before the tablet could be prescribed on the NHS, and that process has not yet begun. For now, access is through private prescription only.

That means the route is the same as for the injection: a licensed online pharmacy or private clinic, a clinical assessment, and a prescription issued by a registered prescriber. If you're still weighing up whether an injection-free option suits you, our page on whether there is a pill version of Wegovy explains the background to that question clearly. The eligibility criteria from the SmPC are broad, adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

If you're exploring what private treatment actually costs and what a legitimate price includes, our weight-loss treatment overview covers the landscape plainly. One thing worth knowing: any legitimate price for a prescription-only medicine includes clinical assessment and a valid prescription. A listing that appears to offer semaglutide tablets without those components is a red flag, not a bargain. The MHRA has been clear on counterfeit weight-loss products sold online, and the same caution applies to tablets as to pens.

The oral version of Wegovy is genuinely new, and if you want to understand the timeline for wider availability, the page covering when the Wegovy pill form is expected to be released sets out what is currently known. The first patients in the UK are only now starting to use it, which means clinical experience is still accumulating. That is not a reason to avoid it, but it is a reason to make that first conversation with a prescriber a real one rather than an online checkout.